Biomarkers in cervical cancer screening

Disease Markers

Volumn 23, Issue 4, 2007, Pages 315-330

  Wentzensen, Nicolas ^a   Von Knebel Doeberitz, Magnus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biomarker; Cervical cancer; HGCIN; HPV; p16INK4a; Screening

Indexed keywords

BIOLOGICAL MARKER; CYCLINE; DNA; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN P16INK4A; TELOMERASE;

CANCER SCREENING; CARCINOGENESIS; CHROMOSOME ABERRATION; GENE EXPRESSION; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; UTERINE CERVIX CANCER; WART VIRUS;

HUMAN PAPILLOMAVIRUS;

EID: 34347324180     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/678793     Document Type: Review

References (133)

1. M.C. Abba, R.M. Laguens, F.N. Dulout and C.D. Golijow, The c-myc activation in cervical carcinomas and HPV 16 infections, Mutat Res 557(2) (2004), 151-158.
2. W.S. Ahn, S.M. Bae, J.M. Lee, S.E. Namkoong, S.J. Han, Y.L. Cho YL et al., Searching for pathogenic gene functions to cervical cancer, Gynecol Oncol 93(1) (2004), 41-48.
3. M. Arbyn, F. Buntinx, M. Van Ranst, E. Paraskevaidis, P. Martin-Hirsch and J. Dillner, Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia, J Natl Cancer Inst 96(4) (2004), 280-293.
4. K.A. Ault, H.K. Allen, S.L. Phillips, M.B. Zimmerman and A.J. Klingelhutz, Telomerase activity as a potential diagnostic marker for triage of abnormal Pap smears, J Low Genit Tract Dis 9(2) (2005), 93-99.
5. C.M. Beausejour, A. Krtolica, F. Galimi, M. Narita, S.W. Lowe, P. Yaswen et al., Reversal of human cellular senescence: roles of the p53 and p16 pathways, EMBO J 22(16) (2003), 4212-4222.
6. L. Berdichevsky, R. Karmin and L. Chuang, Treatment of high-grade squamous intraepithelial lesions: a 2- versus 3-step approach, Am J Obstet Gynecol 190(5) (2004), 1424-1426.
7. B. Bhattacharjee and S. Sengupta, CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology 2006.
8. R. Bollmann, M. Bollmann, D.E. Henson and M. Bodo, DNA cytometry confirms the utility of the Bethesda system for the classification of Papanicolaou smears, Cancer 93(3) (2001), 222-228.
9. R. Bollmann, G. Mehes, R. Torka, N. Speich, C. Schmitt and M. Bollmann, Determination of features indicating progression in atypical squamous cells with undetermined significance: human papillomavirus typing and DNA ploidy analysis from liquid-based cytologic samples, Cancer 99(2) (2003), 113-117.
10. M. Branca, M. Ciotti, C. Giorgi, D. Santini, L. Di Bonito, S. Costa et al., Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN, Anticancer Res 26(2B) (2006), 1543-1556.
11. M. Branca, M. Ciotti, D. Santini, L.D. Bonito, A. Benedetto, C. Giorgi et al., Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer, Am J Clin Pathol 122(6) (2004), 902-911.
12. M. Branca, S. Costa, L. Mariani, F. Sesti, A. Agarossi, A. di Carlo et al., Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study, Eur J Gynaecol Oncol 25(6) (2004), 689-698.
13. M. Branca, C. Giorgi, M. Ciotti, D. Santini, L. Di Bonito, S. Costa et al., Down-regulated nucleoside diphosphate (NDP) kinase nm23-h1 expression is unrelated to high-risk human papillomavirus (HPV) but associated with progression of cin and unfavourable prognosis in cervical cancer, J Clin Pathol (2006).
14. M. Branca, C. Giorgi, M. Ciotti, D. Santini, L. Di Bonito, S. Costa et al., Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer, Eur J Gynaecol Oncol 27(3) (2006), 215-223.
15. M. Branca, C. Giorgi, M. Ciotti, D. Santini, L. Di Bonito, S. Costa et al., Over-Expression of Topoisomerase IIalpha is Related to the Grade of Cervical Intraepithelial Neoplasia (CIN) and High-Risk Human Papillomavirus (HPV), but does not Predict Prognosis in Cervical Cancer or HPV Clearance after Cone Treatment, Int J Gynecol Pathol 25(4) (2006), 383-392.
16. M. Branca, C. Giorgi, M. Ciotti, D. Santini, L. Di Bonito, S. Costa et al., Relationship of up-regulation of 67-kd laminin receptor to grade of cervical intraepithelial neoplasia and to high-risk HPV types and prognosis in cervical cancer, Acta Cytol 50(1) (2006), 6-15.
17. M. Branca, C. Giorgi, M. Ciotti, D. Santini, L. Di Bonito, S. Costa et al., Upregulation of nuclear factor-kappaB (NFkappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer, Diagn Cytopathol 34(8) (2006), 555-563.
18. M. Branca, C. Giorgi, D. Santini, L. Di Bonito, M. Ciotti, A. Benedetto et al., Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer, J Clin Pathol 59(1) (2006), 40-47.
19. M. Branca, C. Giorgi, D. Santini, L. Di Bonito, M. Ciotti, S. Costa et al., Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer, Am J Clin Pathol 124(1) (2005), 113-121.
20. F. Carozzi, S. Cecchini, M. Confortini, V. Becattini, M.P. Cariaggi, G. Pontenani et al., Role of P16((INK4a)) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology, Cancer (2006).
21. P.E. Castle, R. Ashfaq, F. Ansari and C.Y. Muller, Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix, Cancer Lett 229(2) (2005), 245-252.
22. P.E. Castle, D. Solomon, M. Schiffman and C.M. Wheeler, Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities, J Natl Cancer Inst 97(14) (2005), 1066-1071.
23. Y. Chen, C. Miller, R. Mosher, X. Zhao, J. Deeds, M. Morrissey et al., Identification of cervical cancer markers by cDNA and tissue microarrays, Cancer Res 63(8) (2003), 1927-1935.
24. J. Cuzick, M.H. Mayrand, G. Ronco, P. Snijders and P. Wardle, Chapter 10: New dimensions in cervical cancer screening, Vaccine 24(Suppl 3) (2006), S90-S97.
25. J. Cuzick, A. Szarewski, H. Cubie, G. Hulman, H. Kitchener, D. Luesley et al., Management ofwomen who test positive for high-risk types of human papillomavirus: the HART study, Lancet 362(9399) (2003), 1871-1876.
26. L. Denny, L. Kuhn, M. De Souza, A.E. Pollack, W. Dupree and T.C. Wright, Jr., Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial, JAMA 294(17) (2005), 2173-2181.
27. S. Duensing and K. Munger, Centrosome abnormalities, genomic instability and carcinogenic progression, Biochim Biophys Acta 1471(2) (2001), M81-M88.
28. S. Duensing and K. Munger, The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability, Cancer Res 62(23) (2002), 7075-7082.
29. M. Durst, D. Glitz, A. Schneider and H. zur Hausen, Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization, Virology 189(1) (1992), 132-140.
30. S. Eaker, H.O. Adami, F. Granath, E. Wilander and P. Sparen, A large population-based randomized controlled trial to increase attendance at screening for cervical cancer, Cancer Epidemiol Biomarkers Prev 13(3) (2004), 346-354.
31. A.A. El Ghobashy, A.M. Shaaban, J. Herod, J. Innes, W. Prime and C.S. Herrington, Overexpression of cyclins A and B as markers of neoplastic glandular lesions of the cervix, Gynecol Oncol 92(2) (2004), 628-634.
32. M.D. Esajas, J.M. Duk, H.W. de Bruijn, J.G. Aalders, P.H. Willemse, W. Sluiter et al., Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer, J Clin Oncol 19(19) (2001), 3960-3966.
33. Q. Feng, A. Balasubramanian, S.E. Hawes, P. Toure, P.S. Sow, A. Dem et al., Detection of hypermethylated genes in women with and without cervical neoplasia, J Natl Cancer Inst 97(4) (2005), 273-282.
34. M.A. Fitzpatrick, M.C. Funk, D. Gius, P.C. Huettner, Z. Zhang, M. Bidder et al., Identification of chromosomal alterations important in the development of cervical intraepithelial neoplasia and invasive carcinoma using alignment of DNA microarray data, Gynecol Oncol (2006).
35. E.L. Franco, J. Cuzick, A. Hildesheim and S. de Sanjose, Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination, Vaccine 24(Suppl 3) (2006), S171-S177.
36. T. Fujimoto, A. Nishikawa, M. Iwasaki, N. Akutagawa, M. Teramoto and R.Kudo, Gene expression profiling in two morphologically different uterine cervical carcinoma cell lines derived from a single donor using a human cancer cDNA array, Gynecol Oncol 93(2) (2004), 446-453.
37. A. Goel, G. Gandhi, S. Batra, S. Bhambhani, V. Zutshi and P. Sachdeva, Visual inspection of the cervix with acetic acid for cervical intraepithelial lesions, Int J Gynaecol Obstet 88(1) (2005), 25-30.
38. M.M. Goel, A. Mehrotra, U. Singh, H.P. Gupta and J.S. Misra, MIB-1 and PCNA immunostaining as a diagnostic adjunct to cervical Pap smear, Diagn Cytopathol 33(1) (2005), 15-19.
39. C.D. Golijow, M.C. Abba, S.A. Mouron, M.A. Gomez and F.N. Dulout, c-myc gene amplification detected in preinvasive intraepithelial cervical lesions, Int J Gynecol Cancer 11(6) (2001), 462-465.
40. M. Guo, L. Hu, M. Baliga, Z. He and M.D. Hughson, The Predictive Value of p16̂(INK4a) and Hybrid Capture 2 Human Papillomavirus Testing for High-Grade Cervical Intraepithelial Neoplasia, Am J Clin Pathol 122(6) (2004), 894-901.
41. C.P. Harris, X.Y. Lu, G. Narayan, B. Singh, V.V. Murty and P.H. Rao, Comprehensive molecular cytogenetic characterization of cervical cancer cell lines, Genes Chromosomes Cancer 36(3) (2003), 233-241.
42. K. Heselmeyer, E. Schrock, M.S. du, H. Blegen, K. Shah, R. Steinbeck et al., Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix, Proc Natl Acad Sci USA 93(1) (1996), 479-484.
43. K. Heselmeyer-Haddad, K. Sommerfeld, N.M. White, N. Chaudhri, L.E. Morrison, N. Palanisamy et al., Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer, Am J Pathol 166(4) (2005), 1229-1238.
44. A. Hidalgo, M. Baudis, I. Petersen, H. Arreola, P. Pina, G. Vazquez-Ortiz et al., Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma, BMC Cancer 5 (2005), 77.
45. A. Hidalgo, C. Schewe, S. Petersen, M. Salcedo, P. Gariglio, K. Schluns et al., Human papilloma virus status and chromosomal imbalances in primary cervical carcinomas and tumour cell lines, Eur J Cancer 36(4) (2000), 542-548.
46. A.H. Hopman, M.A. Kamps, F. Smedts, E.J. Speel, C.S. Herrington and F.C. Ramaekers, HPV in situ hybridization: impact of different protocols on the detection of integrated HPV, Int J Cancer 115(3) (2005), 419-428.
47. F.Y. Huang, P.M. Chiu, K.F. Tam, Y.K. Kwok, E.T. Lau, M.H. Tang et al., Semi-quantitative fluorescent PCR analysis identifiesPRKAA1on chromosome 5 as a potential candidate cancer gene of cervical cancer, Gynecol Oncol 103(1) (2006), 219-225.
48. F.Y. Huang, Y.K. Kwok, E.T. Lau, M.H. Tang, T.Y. Ng and H.Y. Ngan, Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas, Cancer Genet Cytogenet 157(1) (2005), 42-48.
49. E.A. Jarboe, L.C. Thompson, D. Heinz, J.A. McGregor and K.R. Shroyer, Telomerase and human papillomavirus as diagnostic adjuncts for cervical dysplasia and carcinoma, Hum Pathol 35(4) (2004), 396-402.
50. S. Jeon, B.L. Allen-Hoffmann and P.F. Lambert, Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells, J Virol 69(5) (1995), 2989-2997.
51. S. Jeon and P.F. Lambert, Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis, Proc Natl Acad Sci USA 92(5) (1995), 1654-1658.
52. M. Kalantari, E. Blennow, B. Hagmar and B. Johansson, Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas, Diagn Mol Pathol 10(1) (2001), 46-54.
53. J.T. Keating, A. Cviko, S. Riethdorf, L. Riethdorf, B.J. Quade, D. Sun et al., Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia, Am J Surg Pathol 25(7) (2001), 884-891.
54. S.N. Khleif, J. DeGregori, C.L. Yee, G.A. Otterson, F.J. Kaye, J.R. Nevins et al., Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity, Proc Natl Acad Sci USA 93(9) (1996), 4350-4354.
55. M. Kirchhoff, H. Rose, B.L. Petersen, J. Maahr, T. Gerdes, C. Lundsteen et al., Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma, Genes Chromosomes Cancer 24(2) (1999), 144-150.
56. R. Klaes, A. Benner, T. Friedrich, R. Ridder, S. Herrington, D. Jenkins et al., p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia, Am J Surg Pathol 26(11) (2002), 1389-1399.
57. R. Klaes, T. Friedrich, D. Spitkovsky, R. Ridder, W. Rudy, U. Petry et al., Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri, Int J Cancer 92(2) (2001), 276-284.
58. R. Klaes, S.M. Woerner, R. Ridder, N. Wentzensen, M. Duerst, A. Schneider et al., Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes, Cancer Res 59(24) (1999), 6132-6136.
59. L.G. Koss, The Papanicolaou test for cervical cancer detection. A triumph and a tragedy, JAMA 261(5) (1989), 737-743.
60. A.J. Kruse, J.P. Baak, T. Helliesen, K.H. Kjellevold, M.G. Bol and E.A. Janssen, Evaluation of MIB-1-positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia, Am J Surg Pathol 26(11) (2002), 1501-1507.
61. K.A. Lee, J.W. Kang, J.H. Shim, C.W. Kho, S.G. Park, H.G. Lee et al., Protein profiling and identification of modulators regulated by human papillomavirus 16 E7 oncogene in HaCaT keratinocytes by proteomics, Gynecol Oncol 99(1) (2005), 142-152.
62. S.Y. Liao and E.J. Stanbridge, Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia, Cancer 88(5) (2000), 1108-1121.
63. F. Luft, R. Klaes, M. Nees, M. Durst, V. Heilmann, P. Melsheimer et al., Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells, Int J Cancer 92(1) (2001), 9-17.
64. F. Mantovani and L. Banks, The human papillomavirus E6 protein and its contribution to malignant progression, Oncogene 20(54) (2001), 7874-7887.
65. S.P. Mathur, R.S. Mathur, E.A. Gray, D. Lane, P.G. Underwood, M. Kohler et al., Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected], Gynecol Oncol 98(3) (2005), 467-483.
66. C.P. Matthews, K.A. Shera and J.K. McDougall, Genomic changes and HPV type in cervical carcinoma, Proc Soc Exp Biol Med 223(3) (2000), 316-321.
67. P. Melsheimer, S. Vinokurova, N. Wentzensen, G. Bastert and M. von Knebel Doeberitz, DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri, Clin Cancer Res 10(9) (2004), 3059-3063.
68. A. Mitsuhashi, K. Suzuka, K. Yamazawa, H. Matsui, K. Seki and S. Sekiya, Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma, Cancer 103(4) (2005), 724-730.
69. R. Molina, X. Filella, J.M. Auge, E. Bosch, A. Torne, J. Pahisa et al., CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA, Anticancer Res 25(3A) (2005), 1765-1771.
70. K. Munger, J.R. Basile, S. Duensing, A. Eichten, S.L. Gonzalez, M. Grace et al., Biological activities and molecular targets of the human papillomavirus E7 oncoprotein, Oncogene 20(54) (2001), 7888-7898.
71. N. Murphy, M. Ring, C.C. Heffron, B. King, A.G. Killalea, C. Hughes et al., p16INK4A, CDC6, and MCM5: predictive biomarkers in cervical preinvasive neoplasia and cervical cancer, J Clin Pathol 58(5) (2005), 525-534.
72. D. Ndisang, V. Budhram-Mahadeo, A. Singer and D.S. Latchman, Widespread elevated expression of the human papilloma virus (HPV)-activating cellular transcription factor Brn-3a in the cervix of women with CIN3 (cervical intraepithelial neoplasia stage 3), Clin Sci (Lond) 98(5) (2000), 601-602.
73. D. Ndisang, F. Lorenzato, M. Sindos, A. Singer and D.S. Latchman, Detection of cervical abnormalities in a developing country using measurement of Brn-3a in cervical smears, Gynecol Oncol 100(1) (2006), 89-94.
74. D. Ndisdang, P.J. Morris, C. Chapman, L. Ho, A. Singer and D.S. Latchman, The HPV-activating cellular transcription factor Brn-3a is overexpressed in CIN3 cervical lesions, J Clin Invest 101(8) (1998), 1687-1692.
75. M. Nees, E. van Wijngaarden, E. Bakos, A. Schneider and M. Durst, Identification of novel molecular markers which correlate with HPV-induced tumor progression, Oncogene 16(19) (1998), 2447-2458.
76. G. Negri, F. Vittadello, F. Romano, A. Kasal, F. Rivasi, S. Girlando et al., P16(INK4a) expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri, Virchows Arch (2004).
77. S. Nieh, S.F. Chen, T.Y. Chu, H.C. Lai and E. Fu, Expression of p16 INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix, Gynecol Oncol 91(1) (2003), 201-208.
78. S. Nieh, S.F. Chen, T.Y. Chu, H.C. Lai, Y.S. Lin, E. Fu et al., Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies, Gynecol Oncol 97(1) (2005), 35-40.
79. J.C. Noel, S. Fernandez-Aguilar, I. Fayt, F. Buxant, M.H. Ansion, P. Simon et al., Laminin-5 gamma 2 chain expression in cervical intraepithelial neoplasia and invasive cervical carcinoma, Acta Obstet Gynecol Scand 84(11) (2005), 1119-1123.
80. A.G. Ostor, Natural history of cervical intraepithelial neoplasia: a critical review, Int J Gynecol Pathol 12(2) (1993), 186-192.
81. J.P. O'Sullivan, R.P. A'Hern, P.A. Chapman, L. Jenkins, R. Smith, A. al Nafussi et al., A case-control study of true-positive versus false-negative cervical smears in women with cervical intraepithelial neoplasia (CIN) III, Cytopathology 9(3) (1998), 155-161.
82. P. Peitsaro, B. Johansson and S. Syrjanen, Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique, J Clin Microbiol 40(3) (2002), 886-891.
83. E.C. Pirog, R.N. Baergen, R.A. Soslow, D. Tam, A.E. DeMattia, Y.T. Chen et al., Diagnostic Accuracy of Cervical Low-Grade Squamous Intraepithelial Lesions Is Improved With MIB-1 Immunostaining, Am J Surg Pathol 26(1) (2002), 70-75.
84. P.H. Rao, H. Arias-Pulido, X.Y. Lu, C.P. Harris, H. Vargas, F.F. Zhang et al., Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma, BMC Cancer 4 (2004), 5.
85. M. Resnick, S. Lester, J.E. Tate, E.E. Sheets, C. Sparks and C.P. Crum, Viral and histopathologic correlates of MN and MIB-1 expression in cervical intraepithelial neoplasia, Hum Pathol 27(3) (1996), 234-239.
86. G. Ronco, N. Segnan, P. Giorgi-Rossi, M. Zappa, G.P. Casadei, F. Carozzi et al., Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial, J Natl Cancer Inst 98(11) (2006), 765-774.
87. S. Sahebali, C.E. Depuydt, G.A. Boulet, M. Arbyn, L.M. Moeneclaey, A.J. Vereecken et al., Immunocytochemistry in liquid-based cervical cytology: Analysis of clinical use following a cross-sectional study, Int J Cancer (2005).
88. S. Sahebali, C.E. Depuydt, K. Segers, L.M. Moeneclaey, A.J. Vereecken, E. Van Marck et al., P16INK4a as an adjunct marker in liquid-based cervical cytology, Int J Cancer 108(6) (2004), 871-876.
89. T. Sano, T. Oyama, K. Kashiwabara, T. Fukuda and T. Nakajima, Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions, Am J Pathol 153(6) (1998), 1741-1748.
90. A.D. Santin, F. Zhan, E. Bignotti, E.R. Siegel, S. Cane, S. Bellone et al., Gene expression profiles of primary cervical cancers, Virology 331(2) (2005), 269-291.
91. V. Shanta, S. Krishnamurthi, C.K. Gajalakshmi, R. Swaminathan and K. Ravichandran, Epidemiology of cancer of the cervix: global and national perspective, J Indian Med Assoc 98(2) (2000), 49-52.
92. K.R. Shroyer, P. Homer, D. Heinz and M. Singh, Validation of a novel immunocytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology, Cancer (2006).
93. I. Silins, E. Avall-Lundqvist, A. Tadesse, K.U. Jansen, U. Stendahl, P. Lenner et al., Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients, Gynecol Oncol 85(2) (2002), 333-338.
94. M. Sindos, D. Ndisang, N. Pisal, C. Chow, A. Deery, A. Singer et al., Detection of cervical neoplasia using measurement of Brn-3a in cervical smears with persistent minor abnormality, Int J Gynecol Cancer 13(4) (2003), 515-517.
95. M. Sindos, D. Ndisang, N. Pisal, C. Chow, A. Singer and D.S. Latchman, Measurement of Brn-3a levels in Pap smears provides a novel diagnostic marker for the detection of cervical neoplasia, Gynecol Oncol 90(2) (2003), 366-371.
96. B. Skyldberg, S. Salo, E. Eriksson, U. Aspenblad, B. Moberger, K. Tryggvason et al., Laminin-5 as a marker of invasiveness in cervical lesions, J Natl Cancer Inst 91(21) (1999), 1882-1887.
97. D. Solomon, D. Davey, R. Kurman, A. Moriarty, D. O'Connor, M. Prey et al., The 2001 Bethesda System: terminology for reporting results of cervical cytology, JAMA 287(16) (2002), 2114-2119.
98. S.A. Southern and C.S. Herrington, Differential cell cycle regulation by low- and high-risk human papillomaviruses in low-grade squamous intraepithelial lesions of the cervix, Cancer Res 58(14) (1998), 2941-2945.
99. M. Spitzer, B.S. Apgar and G.L. Brotzman, Management of histologic abnormalities of the cervix, Am Fam Physician 73(1) (2006), 105-112.
100. R.D. Steenbergen, D. Kramer, B.J. Braakhuis, P.L. Stern, R.H. Verheijen, C.J. Meijer et al., TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia, J Natl Cancer Inst 96(4) (2004), 294-305.
101. M. Steinau, D.R. Lee, M.S. Rajeevan, S.D. Vernon, M.T. Ruffin and E.R. Unger, Gene expression profile of cervical tissue compared to exfoliated cells: impact on biomarker discovery, BMC Genomics 6(1) (2005), 64.
102. M.H. Stoler, C.R. Rhodes, A. Whitbeck, S.M. Wolinsky, L.T. Chow and T.R. Broker, Human papillomavirus type 16 and 18 gene expression in cervical neoplasias, Hum Pathol 23(2) (1992), 117-128.
103. E.C. Thorland, S.L. Myers, D.H. Persing, G. Sarkar, R.M. McGovern, B.S. Gostout et al., Human papillomavirus type 16 integrations in cervical tumors frequently occur in common fragile sites, Cancer Res 60(21) (2000), 5916-5921.
104. INK4a - Positive Cells in Cervical Cytology Samples, Acta Cytol 48(6) (2004), 771-782.
105. K. Umayahara, F. Numa, Y. Suehiro, A. Sakata, S. Nawata, H. Ogata et al., Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression, Genes Chromosomes Cancer 33(1) (2002), 98-102.
106. S. Vinokurova, N. Wentzensen, J. Einenkel, R. Klaes, C. Ziegert, P. Melsheimer et al., Clonal history of papillomavirus-induced dysplasia in the female lower genital tract, J Natl Cancer Inst 97(24) (2005), 1816-1821.
107. M. von Knebel Doeberitz, T. Bauknecht, D. Bartsch and H. zur Hausen, Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells, Proc Natl Acad Sci USA 88(4) (1991), 1411-1415.
108. M. von Knebel Doeberitz, New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections, Eur J Cancer 38(17) (2002), 2229-2242.
109. J.L. Wang, B.Y. Zheng, X.D. Li, T. Angstrom, M.S. Lindstrom and K.L. Wallin, Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer, Clin Cancer Res 10(7) (2004), 2407-2414.
110. S.S. Wang, M.E. Sherman, A. Hildesheim, J.V. Lacey, Jr. and S. Devesa, Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000, Cancer 100(5) (2004), 1035-1044.
111. S.S. Wang, M. Trunk, M. Schiffman, R. Herrero, M.E. Sherman, R.D. Burk et al., Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica, Cancer Epidemiol Biomarkers Prev 13(8) (2004), 1355-1360.
112. T. Waterboer, P. Sehr, K.M. Michael, S. Franceschi, J.D. Nieland, T.O. Joos et al., Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins, Clin Chem 51(10) (2005), 1845-1853.
113. E.J. Weaver, A.J. Kovatich and M. Bibbo, Cyclin E expression and early cervical neoplasia in ThinPrep specimens. A feasibility study, Acta Cytol 44(3) (2000), 301-304.
114. N. Wentzensen, C. Bergeron, F. Cas, D. Eschenbach, S. Vinokurova and M. von Knebel Doeberitz, Evaluation of a nuclear score for p16INK4a-stained cervical squamous cells in liquid-based cytology samples, Cancer 105(6) (2005), 461-467.
115. N. Wentzensen, M. Hampl, M. Herkert, A. Reichert, M.J. Trunk, C. Poremba et al., Identification of high-grade cervical dysplasia by the detection of p16(INK4a) in cell lysates obtained from cervical samples, Cancer 107(9) (2006), 2307-2313.
116. N. Wentzensen, R. Ridder, R. Klaes, S. Vinokurova, U. Schaefer and M. von Knebel Doeberitz, Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions, Oncogene 21(3) (2002), 419-426.
117. N. Wentzensen, S. Vinokurova and M. von Knebel Doeberitz, Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract, Cancer Res 64(11) (2004), 3878-3884.
118. S.P. Wheatley and I.A. McNeish, Survivin: a protein with dual roles in mitosis and apoptosis, Int Rev Cytol 247 (2005), 35-88.
119. A. Widschwendter, L. Ivarsson, A. Blassnig, H.M. Muller, H. Fiegl, A. Wiedemair et al., CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients, Int J Cancer 109(2) (2004), 163-166.
120. G.H. Williams, P. Romanowski, L. Morris, M. Madine, A.D. Mills, K. Stoeber et al., Improved cervical smear assessment using antibodies against proteins that regulate DNA replication, Proc Natl Acad Sci USA 95(25) (1998), 14932-14937.
121. V. Wollscheid, R. Kuhne-Heid, I. Stein, L. Jansen, S. Kollner, A. Schneider et al., Identification of a new proliferation-associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomas, Int J Cancer 99(6) (2002), 771-775.
122. Y.F. Wong, T.H. Cheung, K.W. Lo, V.W. Wang, C.S. Chan, T.B. Ng et al., Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix, Cancer Lett 211(2) (2004), 227-234.
123. Y.F. Wong, Z.E. Selvanayagam, N. Wei, J. Porter, R. Vittal, R. Hu et al., Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray, Clin Cancer Res 9(15) (2003), 5486-5492.
124. T.C. Wright, Jr., J.T. Cox, L.S. Massad, J. Carlson, L.B. Twiggs and E.J. Wilkinson, 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia, Am J Obstet Gynecol 189(1) (2003), 295-304.
125. T.C. Wright, Jr., J.T. Cox, L.S. Massad, L.B. Twiggs and E.J. Wilkinson, 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities, JAMA 287(16) (2002), 2120-2129.
126. T.C. Wright, Jr., M. Schiffman, D. Solomon, J.T. Cox, F. Garcia, S. Goldie et al., Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening, Obstet Gynecol 103(2) (2004), 304-309.
127. Y.C. Yang, W.Y. Shyong, M.S. Chang, Y.J. Chen, C.H. Lin, Z.D. Huang et al., Frequent gain of copy number on the long arm of chromosome 3 in human cervical adenocarcinoma, Cancer Genet Cytogenet 131(1) (2001), 48-53.
128. T. Yoshida, T. Fukuda, T. Sano, T. Kanuma, N. Owada and T. Nakajima, Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials, Cancer 102(2) (2004), 100-108.
129. M.Y. Yu, J.H. Tong, P.K. Chan, T.L. Lee, M.W. Chan, A.W. Chan et al., Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers, Int J Cancer 105(2) (2003), 204-209.
130. A. Zhang, J. Wang, B. Zheng, X. Fang, T. Angstrom, C. Liu et al., Telomere attrition predominantly occurs in precursor lesions during in vivo carcinogenic process of the uterine cervix, Oncogene 23(44) (2004), 7441-7447.
131. C. Ziegert, N. Wentzensen, S. Vinokurova, F. Kisseljov, J. Einenkel, M. Hoeckel et al., A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques, Oncogene 22(25) (2003), 3977-3984.
132. H. zur Hausen, Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes, Semin Cancer Biol 9(6) (1999), 405-411.
133. H. zur Hausen, Papillomaviruses and cancer: from basic studies to clinical application, Nat Rev Cancer 2(5) (2002), 342-350.